Details of the Drug
General Information of Drug (ID: DM724JF)
Drug Name |
5,7-Dimethoxy-3-pyridin-4-yl-quinoline
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5,7-Dimethoxy-3-(4-pyridinyl)quinoline; 137206-97-4; 5,7-dimethoxy-3-(pyridin-4-yl)quinoline; CHEMBL68423; Quinoline,5,7-dimethoxy-3-(4-pyridinyl)-; 5,7-Dmpq; Bio1_000429; Tocris-1222; 5,7-Dimethoxy-3-pyridin-4-yl-quinoline; ACMC-20c86u; AC1L1F9B; AC1Q4YD3; SCHEMBL3652915; CTK4C0691; DTXSID90160107; Bio1_001407; Bio1_000918; ZINC2581408; BDBM50039655; AKOS030239521; 5,7-Dimethoxy-3-(4-pyridyl)quinoline; 5,7-dimethoxy-3-pyridin-4-ylquinoline; NCGC00025053-01; AJ-43025; KB-291722; DB-063190
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 266.29 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||